ReviewCancers2021
Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Recent Advancement in Drug Designing as Small Molecules in Targeted Cancer Therapy: Challenges and Future Directions.Current cancer drug targets · 2025Review
- Analysis of Pan-Specific Inhibitors of Oncogenic Mutant Forms of KRAS GTPase.Current medicinal chemistry · 2025Review
- Nonsmall-cell lung cancer treatment: current status of drug repurposing and nanoparticle-based drug delivery systems.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- Clinical perspectives on the value of testing forFrontiers in oncology · 2024Article
- Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams.Cancers · 2023Review
- Recent advances in non-small cell lung cancer targeted therapy; an update review.Cancer cell international · 2023Review
- NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs.International journal of molecular sciences · 2022Article
- Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with aJournal of clinical medicine · 2022Article
- Synthetic Vulnerabilities in the KRAS Pathway.Cancers · 2022Review
- A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib.Lung Cancer (Auckland, N.Z.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene mutations are among the most common driver alterations in non-small cell lung cancer (NSCLC). Despite their high frequency, valid treatment options are still lacking, mainly due to an intrinsic complexity of both the protein structure and the downstream pathway. The increasing knowledge about different mutation subtypes and co-mutations has paved the way to several promising therapeutic strategies. Despite the best results so far having been obtained in patients harbouring KRAS exon 2 p.G12C mutation, even the treatment landscape of non-p.G12C KRAS mutation positive patients is predicted to change soon. This review provides a comprehensive and critical overview of ongoing studies into NSCLC patients with KRAS mutations other than p.G12C and discusses future scenarios that will hopefully change the story of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.